CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies for patients with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Its lead investigational candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy currently advancing through two Phase 3 clinical trials—BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC—as well as the Phase 2 CORE-008 study combining it with a checkpoint inhibitor for high-risk BCG-unresponsive disease. The company targets urologic cancers, addressing significant unmet needs in BCG-unresponsive and intermediate-risk settings where durable, bladder-preserving options are limited. Headquartered in Irvine, California, CG Oncology engages in clinical development, regulatory interactions including a rolling Biologics License Application submission and Fast Track designation, and supports research through programs like fellowships at urologic conferences. This positions CG Oncology as a key player in oncology biotechnology, emphasizing innovative intravesical therapies to improve patient outcomes in bladder cancer treatment.